🇺🇸 FDA
Patent

US 11986534

Treatment of anthrax with pegylated capsule-degrading enzyme

granted A61KA61K38/45A61K47/60

Quick answer

US patent 11986534 (Treatment of anthrax with pegylated capsule-degrading enzyme) held by The Government of the United States of America, as represented by the Secretary of the Navy expires Mon May 16 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Government of the United States of America, as represented by the Secretary of the Navy
Grant date
Tue May 21 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 16 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
5
CPC classes
A61K, A61K38/45, A61K47/60